The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Radiographic progression without PSA progression in metastatic hormone-sensitive prostate cancer (mHSPC): A retrospective analysis from the ENZAMET trial (ANZUP 1304).
 
Ian D. Davis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Ipsen (Inst); Janssen Oncology (Inst); Medivation (Inst); Movember Foundation (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research.
 
Andrew James Martin
No Relationships to Disclose
 
Robert Richard Zielinski
Honoraria - AstraZeneca; Janssen Oncology
Research Funding - AstraZeneca (Inst); BMSi (Inst)
 
Alastair Thomson
Consulting or Advisory Role - MSD; Novartis
Speakers' Bureau - Genomic Health; Gilead Sciences; Lilly; Novartis; Roche
Travel, Accommodations, Expenses - Astellas Pharma; BMS; EUSA Pharma; Ipsen; MSD
 
Thean Hsiang Tan
Speakers' Bureau - Ipsen; Janssen Oncology
 
Shahneen Sandhu
Honoraria - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb/Roche (Inst); Merck Sharp and Dohme (Inst); Novartis (Inst)
Speakers' Bureau - AstraZeneca (Inst); Bristol-Myers Squibb; Merck; Roche/Genentech
Research Funding - Amgen (Inst); AstraZeneca (Inst); Endocyte/Advanced Accelerator Applications (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Senhwa Biosciences (Inst)
(OPTIONAL) Uncompensated Relationships - AAA/Endocyte/Novartis (Inst)
 
M. Neil Reaume
Honoraria - Astellas Pharma; Astellas Pharma; AstraZeneca; EMD serono; Ipsen; Novartis; Pfizer
Research Funding - AstraZeneca
 
David William Pook
Honoraria - Bayer; Merck/Pfizer
Consulting or Advisory Role - Astellas Pharma; Bristol Myers Squibb Foundation; Bristol-Myers Squibb; Bristol-Myers Squibb; Cipla; Merck; Merck Sharp & Dohme; Merck Sharp & Dohme (Inst); Merck/Pfizer; Merck/Pfizer; Pfizer; Pfizer (Inst)
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche (Inst); SymVivo (Inst)
Travel, Accommodations, Expenses - Amgen; Amgen; Astellas Pharma; Bristol-Myers Squibb; Janssen; Merck/Pfizer; Merck/Pfizer; Pfizer
 
Francis Parnis
Stock and Other Ownership Interests - Telix Pharmaceuticals
Consulting or Advisory Role - Ipsen; Janssen Oncology; Merck Serono
Speakers' Bureau - AstraZeneca
Other Relationship - Bayer Schering Pharma
 
Scott A. North
No Relationships to Disclose
 
Gavin M. Marx
No Relationships to Disclose
 
John McCaffrey
Travel, Accommodations, Expenses - Pfizer
 
Raymond S. McDermott
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Clovis Oncology; Ipsen; Janssen; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi
Speakers' Bureau - MSD Oncology
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Ipsen; Janssen-Cilag; Pfizer; Roche
 
Andrisha Jade Inderjeeth
Honoraria - BMS; Pfizer
 
Lisa Horvath
Employment - Connected Medical Solutions (I)
Leadership - ANZUP; Connected Medical Solutions (I)
Stock and Other Ownership Interests - Connected Medical Solutions (I); Imagion Biosystems
Honoraria - ANZUP; Astellas Pharma; Bayer; Janssen
Consulting or Advisory Role - Astellas Pharma; Bayer; Imagion Biosystems
Research Funding - Astellas Pharma
Patents, Royalties, Other Intellectual Property - Provisional patent Australian No. 2022902527 Prognostic Markers (plasma lipid prognostic signature in metastatic prostate cancer). Inventors: Horvath L, Meikle P, Scheinberg S, Lin HM, Sullivan D The patent is owned by the Chris O'Brien Lifehouse (my (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen-Cilag; MSD Oncology; Pfizer
 
Mark Frydenberg
Leadership - Genesis Cancer Care
Stock and Other Ownership Interests - Telix Pharmaceuticals (I)
 
Simon Chowdhury
No Relationships to Disclose
 
Kim N. Chi
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck; POINT Biopharma; Roche
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Constellation Pharmaceuticals; Daiichi Sankyo; ESSA; Janssen; Merck; POINT Biopharma; Roche; Sanofi
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); ESSA (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
Expert Testimony - AstraZeneca; Novartis
 
Martin R. Stockler
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Tilray (Inst)
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Cadence Pharma; Genentech/Roche; Janssen Biotech; Lilly; Pfizer; POINT Biopharma; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon; Janssen Biotech (Inst); Pfizer (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination